Used in research for the treatment of hepatitis B virus (HBV) infection. Acts as a core protein allosteric modulator (CpAM), disrupting the normal assembly of the viral capsid, which is essential for viral replication. This compound interferes with the formation of functional capsids, leading to the production of non-infectious viral particles and reducing the overall viral load. It is studied for its potential to enhance current antiviral therapies by targeting a different stage of the HBV life cycle. Also used as a reference compound in virology and drug development studies focused on capsid assembly inhibitors.